The latest breakthroughs in science-based cancer therapy.
Clinical trials are controlled tests conducted to evaluate if new treatments are more effective than those currently available. Sometimes, treatments evaluated in clinical trials are proved to be even more beneficial than existing treatment. In […]
A new vaccine may offer a new treatment option to cancer diagnosed with a rare, aggressive brain cancer called glioblastoma multiforme (GBM). A large international clinical trial has shown this vaccine can extend […]
The FDA has just approved brentuximab vedotin to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy, an approval that “represents an improvement in […]
On Friday, January 26, 2018, The US Food and Drug Administration (FDA) announced its approval of Lutathera for certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of cancer that affects the […]
A new weapon in the battle against lung cancer has just been approved for use. The Food and Drug Administration has just approved Gilotrif for non-resistant EFGR mutations in lung cancer treatment, […]
The Food and Drug Administration (FDA) recently approved a promising new drug treatment, brentuximab vedotin, for either of two types of non-Hodgkin lymphoma. The drug’s market name will be Adcetris. […]
According to the American Cancer Society, five-year survival rates for people diagnosed with localized melanoma are high at 98%. However, more innovate treatment options are needed for anyone diagnosed with […]
Yesterday, the Federal Drug Administration (FDA) granted Roche subsidiary Genentech’s pertuzumab regular approval for treatment for HER2-Positive early breast cancer patients at high risk of recurrence. […]
President Jimmy Carter gained national attention when he announced that his doctors could no longer find any proof of melanoma in his body. That exciting news was due in large part to a ground-breaking type […]
Copyright © 2016-2024 | Cancer Care News | All Rights Reserved
